Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chemokine (C-C motif) ligand 24 is a member of the CC chemokine family, distinguished by the presence of two adjacent cysteines. Primarily secreted by monocytes, macrophages, and bronchial epithelial cells, CCL24 exerts a strong chemotactic influence on eosinophils and, to a lesser degree, resting T lymphocytes and neutrophils. Its biological activity is closely linked to inflammatory and allergic disorders, where elevated levels are a hallmark of disease. CCL24 interacts with the chemokine receptor CCR3 to mediate immune cell recruitment in tissues. The molecule has demonstrated implications not only in the regulation of inflammation but also in disease modulation, such as diabetic nephropathy, by controlling tissue infiltration of immune cells and fibrosis. Research into CCL24 as a therapeutic target seeks to reduce pathological inflammation in severe allergic and chronic inflammatory conditions.
Drugs or antibodies targeting CCL24 typically act by inhibiting its binding to CCR3 receptor, thereby reducing eosinophil and lymphocyte chemotaxis and subsequent inflammation
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chemokine (C-C motif) ligand 24 (CCL24).